UY27615A1 - Acidos 3 - (imidazolil) - 2 alcoxipropanoicos - Google Patents

Acidos 3 - (imidazolil) - 2 alcoxipropanoicos

Info

Publication number
UY27615A1
UY27615A1 UY27615A UY27615A UY27615A1 UY 27615 A1 UY27615 A1 UY 27615A1 UY 27615 A UY27615 A UY 27615A UY 27615 A UY27615 A UY 27615A UY 27615 A1 UY27615 A1 UY 27615A1
Authority
UY
Uruguay
Prior art keywords
alcoxipropanoics
imidazolil
acids
alkyl
hydrogen
Prior art date
Application number
UY27615A
Other languages
English (en)
Inventor
Mark E Bunnage
Robert J Maguire
Kohn Steele
Daavid J Bulll
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of UY27615A1 publication Critical patent/UY27615A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de acuerdo con la fórmula ( I ) en la que n el 0-3, R1 es alquilo C1-6 opcionalmente sustituido, alquenilo C2-6 o alquinilo C2-6, heterociclo aromático, arilo o hidrógeno y cada uno de R2, R3, R4, R5, R6, R7,R8, y R9, selecciona independientemente entre 10 hidrógeno y alquilo C1-6 opcionalmente sustituido, o R5, y R8, son una cadena alquileno, son novedosos. Estos compuestos son útiles en el tratamiento de afecciones trombóticas y otras patalogías asociadas con la deposición de fibrina.
UY27615A 2002-01-22 2003-01-20 Acidos 3 - (imidazolil) - 2 alcoxipropanoicos UY27615A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids

Publications (1)

Publication Number Publication Date
UY27615A1 true UY27615A1 (es) 2003-08-29

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27615A UY27615A1 (es) 2002-01-22 2003-01-20 Acidos 3 - (imidazolil) - 2 alcoxipropanoicos

Country Status (24)

Country Link
EP (1) EP1467731A1 (es)
JP (1) JP2005520811A (es)
KR (1) KR20040077775A (es)
CN (1) CN1620291A (es)
AP (1) AP2004003084A0 (es)
AR (1) AR038197A1 (es)
BR (1) BR0307016A (es)
CA (1) CA2472238A1 (es)
EA (1) EA200400716A1 (es)
EC (1) ECSP045200A (es)
HR (1) HRP20040659A2 (es)
IL (1) IL162677A0 (es)
IS (1) IS7310A (es)
MA (1) MA27167A1 (es)
MX (1) MXPA04006573A (es)
NO (1) NO20043457L (es)
OA (1) OA12756A (es)
PA (1) PA8563501A1 (es)
PE (1) PE20030929A1 (es)
PL (1) PL371487A1 (es)
TN (1) TNSN04121A1 (es)
TW (1) TW200302094A (es)
UY (1) UY27615A1 (es)
WO (1) WO2003061652A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
EP1874322A1 (en) * 2005-04-18 2008-01-09 Bayer Schering Pharma Aktiengesellschaft Use of tafi inhibitors for enhanced myocardial reperfusion and facilitated pci
US20110213143A1 (en) 2008-10-29 2011-09-01 Taisho Pharmaceutical Co., Ltd. Compound having tafia inhibitory activity
JP2012511008A (ja) * 2008-12-05 2012-05-17 持田製薬株式会社 IXa因子阻害薬としてのモルホリノン化合物
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
KR20130006620A (ko) 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 시클로프로판카르복실산 유도체
DK2548871T3 (da) * 2010-03-18 2017-11-06 Daiichi Sankyo Co Ltd Cycloalkylsubstitueret imidazolderivat
CN105263928A (zh) 2013-06-10 2016-01-20 赛诺菲 作为TAFIa的抑制剂的大环脲衍生物、其制备及其作为药物的用途
CN108883094A (zh) 2016-03-29 2018-11-23 第三共株式会社 炎症性肠病治疗剂
MX2020002944A (es) 2017-09-14 2020-09-28 Daiichi Sankyo Co Ltd Compuesto que tiene estructura ciclica.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (sv) * 1999-05-03 1999-05-03 Astra Ab New compounds
DE60140368D1 (de) * 2000-08-17 2009-12-17 Pfizer Ltd Substitutuierte imidazole als tafia inhibitoren

Also Published As

Publication number Publication date
EA200400716A1 (ru) 2004-12-30
OA12756A (en) 2006-07-03
WO2003061652A8 (en) 2004-09-10
JP2005520811A (ja) 2005-07-14
ECSP045200A (es) 2004-08-27
BR0307016A (pt) 2004-11-03
AR038197A1 (es) 2005-01-05
IS7310A (is) 2004-06-14
TNSN04121A1 (en) 2006-06-01
TW200302094A (en) 2003-08-01
PE20030929A1 (es) 2003-11-05
HRP20040659A2 (en) 2004-10-31
NO20043457L (no) 2004-08-19
PL371487A1 (en) 2005-06-13
CN1620291A (zh) 2005-05-25
PA8563501A1 (es) 2004-08-31
KR20040077775A (ko) 2004-09-06
MXPA04006573A (es) 2004-10-04
MA27167A1 (fr) 2005-01-03
EP1467731A1 (en) 2004-10-20
WO2003061652A1 (en) 2003-07-31
CA2472238A1 (en) 2003-07-31
IL162677A0 (en) 2005-11-20
AP2004003084A0 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
UY27522A1 (es) Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
NO20005237L (no) Heterocyklisk substituerte amider anvendt som calpain- inhibitorer
ATE396993T1 (de) Tetrahydropyranyl-cyclopentyl- tetrahydropyridopyridin-modulatoren der chemokin- rezeptor-aktivität
CY1107903T1 (el) Παραγωγα ακυλαμινοθειαζολης και η χρηση τους ως αναστολεις του βητα-αμυλοειδους
ES2184280T3 (es) Compuestos de indol como inhibidores de cox-2'.
PE20040688A1 (es) Inhibidores de quinasas
NO20065178L (no) Tienopyridinderivater
DE60322877D1 (de) Tetrahydropyranylcyclopentyltetrahydroisochino-linmodulatoren der chemokinrezeptoraktivität
ES2186874T3 (es) Analogos de m-amidinofenilo como inhibidores del factor xa.
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
UY27615A1 (es) Acidos 3 - (imidazolil) - 2 alcoxipropanoicos
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
PE20040528A1 (es) Inhibidores de la peptido-deformilasa
NO20050612L (no) Pyrrolidinderivater som oksytocinantagonister
PE20060103A1 (es) Nuevas 5-acilindolinonas con contenido en cicloalquilo y su preparacion como medicamento
PE29798A1 (es) Acetidinas
MXPA04005940A (es) Acidos 3-(imidazolil)-2-aminopropanoicos.
PE20050231A1 (es) Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3
PE20030611A1 (es) Compuestos basicos lineales que tienen actividad antagonista de nk-2 y sus formulaciones
AR054414A1 (es) Compuestos espiro-hidantoina sustituidos con piridilo. composiciones farmaceuticas.
PE20050120A1 (es) Camptotecinas con un anillo de lactona modificada
DE60124717D1 (de) Aryl-sulfonamide als serotonin-antagonisten für de behandlung von fettleibigkeit
DOP2003000564A (es) Acidos 3-(imidazolil)-2-alcoxipropanoicos
CO5540311A2 (es) Derivados de pirimidina utiles como inhibidores de cox-2 selectivos
UY27616A1 (es) Acidos 3 - (amidazolil ) - aminopropanoicos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126